Oryzon Genomics SA (ORY)

Currency in EUR
2.635
+0.025(+0.96%)
Delayed Data·
ORY Scorecard
Full Analysis
Net income is expected to drop this year
ORY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.6202.665
52 wk Range
1.4003.690
Key Statistics
Bid/Ask
2.63 / 2.635
Prev. Close
2.61
Open
2.635
Day's Range
2.62-2.665
52 wk Range
1.4-3.69
Volume
187.57K
Average Volume (3m)
491.54K
1-Year Change
45.48%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ORY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.783
Upside
+157.43%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Oryzon Genomics SA Company Profile

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

Compare ORY to Peers and Sector

Metrics to compare
ORY
Peers
Sector
Relationship
P/E Ratio
−47.9x−0.8x−0.5x
PEG Ratio
-−0.090.00
Price/Book
1.8x2.6x2.6x
Price / LTM Sales
27.1x6.7x3.3x
Upside (Analyst Target)
66.7%55.7%43.5%
Fair Value Upside
Unlock20.2%6.3%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 6.783
(+157.43% Upside)

Earnings

Latest Release
Jul 30, 2025
EPS / Forecast
-- / -0.0266
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ORY Income Statement

People Also Watch

13.067
REP
+1.37%
7.5010
SAN
+0.28%
36.850
IDR
+2.19%
13.025
GRLS
+0.73%
3.1640
SABE
-0.44%

FAQ

What Stock Exchange Does Oryzon Genomics Trade On?

Oryzon Genomics is listed and trades on the Madrid Stock Exchange stock exchange.

What Is the Stock Symbol for Oryzon Genomics?

The stock symbol for Oryzon Genomics is "ORY."

What Is the Oryzon Genomics Market Cap?

As of today, Oryzon Genomics market cap is 204.63M.

What Is Oryzon Genomics's Earnings Per Share (TTM)?

The Oryzon Genomics EPS (TTM) is 0.00.

When Is the Next Oryzon Genomics Earnings Date?

Oryzon Genomics will release its next earnings report on 22 Oct 2025.

From a Technical Analysis Perspective, Is ORY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Oryzon Genomics Stock Split?

Oryzon Genomics has split 0 times.

How Many Employees Does Oryzon Genomics Have?

Oryzon Genomics has 47 employees.

What is the current trading status of Oryzon Genomics (ORY)?

As of 05 Aug 2025, Oryzon Genomics (ORY) is trading at a price of 2.64, with a previous close of 2.61. The stock has fluctuated within a day range of 2.62 to 2.67, while its 52-week range spans from 1.40 to 3.69.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.